deltatrials
Completed PHASE2 NCT00062114

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma

Sponsor: Alliance for Clinical Trials in Oncology

Conditions Lymphoma
Interventions rituximab yttrium Y 90 ibritumomab tiuxetan
Updated 7 times since 2017 Last updated: Jul 1, 2016 Started: Apr 30, 2004 Primary completion: Apr 30, 2007 Completion: Apr 30, 2007

Listed as NCT00062114, this PHASE2 trial focuses on Lymphoma and remains completed. Sponsored by Alliance for Clinical Trials in Oncology, it has been updated 7 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alliance for Clinical Trials in Oncology
  • National Cancer Institute (NCI)
Data source: Alliance for Clinical Trials in Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

American Fork, United States, Anderson, United States, Aurora, United States, Beech Grove, United States, Berlin Corners, United States, Bethlehem, United States, Billings, United States, Boston, United States, Bozeman, United States, Burbank, United States and 55 more location s